Orchestra BioMed Hldgs Q1 EPS $(0.38) Beats $(0.41) Estimate, Sales $620.00K Miss $940.00K Estimate

5/13/24 5:00:19 PM ET

Medicinal Chemicals and Botanical Products

Health Care

Get the next $OBIO alert in real time by email

Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.32 percent. This is a 5 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $620.00 thousand which missed the analyst consensus estimate of $940.00 thousand by 34.04 percent. This is a 46.74 percent decrease over sales of $1.16 million the same period last year.

Get the next $OBIO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OBIO

Date	Price Target	Rating	Analyst
8/22/2024	$14.00	Buy	H.C. Wainwright
7/25/2024	$15.00	Buy	B. Riley Securities
1/19/2024	$14.00	Buy	Jefferies
2/24/2023	$15.00	Overweight	Piper Sandler
2/7/2023	$20.00	Buy	Chardan Capital Markets

More analyst ratings

$OBIO
Press Releases

Fastest customizable press release news feed in the world

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update
NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its third quarter 2024 financial results and provided a business update. "The Orchestra BioMed team is focused on execution of the BACKBEAT global pivotal study alongside our strategic partner, Medtronic. We are excited about the enthusiasm we have seen from the clinical community for the potential of AVIM therapy to provide these typically older, higher risk hypertension patients with a potent, programmable, always on t
11/12/24 4:12:39 PM ET
$HAE
$MDT
$OBIO
Medical/Dental Instruments
Health Care
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Medicinal Chemicals and Botanical Products
Orchestra BioMed to Participate in Jefferies London Healthcare Conference
NEW HOPE, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Jefferies London Healthcare Conference being held in London, UK from November 19-21, 2024. Details of the presentation are shown below. Format: Fireside Chat Date: Tuesday, November 19, 2024 Time: 1:00 PM GMT Webcast: https://wsw.com/webcast/jeff315/obio/1840692 A replay of the webcast will be available on the Events section of the Orchest
11/7/24 8:00:00 AM ET
$OBIO
Medicinal Chemicals and Botanical Products
Health Care
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2024 financial results and provided a business update. "Our work in hypertension and coronary artery disease aligns with a renaissance occurring in cardiac pacing and balloon angioplasty, applying new innovations to enhance these foundational device-based interventions and create more potent therapeutic solutions. At our inaugural R&D day in June, we were excited to share our insights into this renais
8/12/24 4:20:20 PM ET
$MDT
$OBIO
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Medicinal Chemicals and Botanical Products

Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors
John Mack brings over 30 years of diverse medical device and healthcare technology experience to the Orchestra BioMed Board of Directors Most recently, Mr. Mack served as Medtronic's President of Cardiac Surgery; Previous Medtronic roles include Vice President, Business Development, Strategy & Portfolio Management NEW HOPE, Pa., July 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of John Mack to its Board of Directors, effective as of July 29, 2024. Mr. Mack brings over 30 years
7/30/24 8:00:00 AM ET
$OBIO
Medicinal Chemicals and Botanical Products
Health Care
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
David Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers; formerly Division Vice President of U.S. Commercial Operations, Sales, and Marketing at Abbott VascularMr. Pacitti brings nearly 30 years of experience in cardiovascular device and procedural imaging experience to the Orchestra BioMed Board of Directors after previously serving as a strategic advisor during the formation of the company NEW HOPE, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward shar
3/26/24 8:00:00 AM ET
$OBIO
Medicinal Chemicals and Botanical Products
Health Care
Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors
FORT LAUDERDALE, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, announced the appointment of Scott Durbin to the Company's Board of Directors (the "Board"). Mr. Durbin has more than 25 years of executive leadership, finance and clinical development experience, including the execution of over $5 billion in financings and merger transactions. In addition, the Company announced that David Hochman and Darren Sherman, independent members of the Board, have stepped down from the Board due to time requirements of their roles as Chief Executive Offi
9/6/23 5:00:42 PM ET
$MOTS
$OBIO
Medical/Dental Instruments
Health Care
Medicinal Chemicals and Botanical Products

Orchestra BioMed Hldgs Q1 EPS $(0.38) Beats $(0.41) Estimate, Sales $620.00K Miss $940.00K Estimate

Chat with this insight

Recent Analyst Ratings for $OBIO

$OBIO SEC Filings

SEC Form 10-Q filed by Orchestra BioMed Holdings Inc.

SEC Form 144 filed by Orchestra BioMed Holdings Inc.

SEC Form 144 filed by Orchestra BioMed Holdings Inc.

$OBIO Financials

Live finance-specific insights

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

$OBIO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Officer Hochman David P bought $47,905 worth of shares (10,000 units at $4.79), increasing direct ownership by 0.44% to 570,498 units (SEC Form 4)

Officer Hochman David P bought $14,600 worth of shares (2,500 units at $5.84), increasing direct ownership by 0.44% to 567,998 units (SEC Form 4)

Officer Hochman David P bought $6,950 worth of shares (1,000 units at $6.95) (SEC Form 4)

$OBIO Market Insights

Live Market Insights

$OBIO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$OBIO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Chardan Capital Reiterates Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target